Phase 1 Open Label Dose-Escalating Study to Evaluate the Safety, Tolerability and Immunogenity of the Recombinant Plague Vaccine rF1V in Healthy Volunteers

Grants and Contracts Details

StatusFinished
Effective start/end date1/21/056/30/12

Funding

  • Covalent Group: $682,761.00